Skip to content
AnalystLens

Halozyme Therapeutics 8-K Report, Financial Results (Jan 17, 2024)

Reports
Earnings & Results
Filing Date
Filed January 17, 2024
Period End
January 17, 2024
Security
HALO
In the record · 2016–202610-K1110-Q338-K141

HALO filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 141 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Leadership change8-K · Feb ’20Feb ’20
  3. Material agreement8-K · Aug ’22Aug ’22
  4. Leadership change8-K · Sep ’26Sep ’26

Summary

Summary of the 8-K filed January 17, 2024. Cited figures are marked; the original filing is the authoritative source.

Halozyme Therapeutics, Inc. hosted a financial update call on January 17, 2024 covering its patent portfolio, 2024 financial guidance and long-term financial outlook.

In connection with that call, the company furnished preliminary, unaudited estimates for the twelve months ended December 31, 2023: revenue of $827 million to $832 milliona and royalties of $445 million to $450 million. Net income is estimated at $292 million to $297 million, EBITDA at $435 million to $440 million, and Adjusted EBITDA at $425 million to $430 million. On a per-share basis, the company estimates 2023 GAAP diluted EPS of $2.18 to $2.21 and Non-GAAP diluted EPS of $2.77 to $2.80, based on 134.2 million diluted shares.

The reconciliations show the Non-GAAP adjustments are driven largely by amortization of intangible assets ($0.55b per share), share-based compensation ($0.27 per share) and a gain on changes in fair value of a contingent liability ($0.10 per share), the latter tied to the September 2023 termination of the TLANDO license agreement, which also led to an inventory write-off and impairment of TLANDO product rights intangibles. The company cautions that these figures are subject to completion of its financial close and audit procedures, and that final results could vary materially.

They are not a substitute for the Form 10-K for 2023 once filed. The estimates are furnished under Item 2.02 and are not deemed filed for purposes of Section 18 of the Exchange Act.

Key Highlights

  1. Estimated 2023 revenue of $827 million to $832 million, with royalties estimated at $445 million to $450 million
  2. Estimated 2023 Net Income of $292 million to $297 million; EBITDA of $435 million to $440 million; Adjusted EBITDA of $425 million to $430 million
  3. Estimated 2023 GAAP diluted EPS of $2.18 to $2.21 and Non-GAAP diluted EPS of $2.77 to $2.80 on 134.2 million diluted shares
  4. TLANDO license agreement terminated in September 2023, producing a $13 million gain on changes in fair value of a contingent liability and a $4 million inventory write-off in the 2023 reconciliation
  5. Amortization of intangible assets of $0.55 per share is the largest Non-GAAP adjustment, including impairment of TLANDO product rights
  6. Financial update call on January 17, 2024 also covered the patent portfolio, 2024 financial guidance and long-term financial outlook
  7. Estimates are preliminary and unaudited and may vary materially from final results reported in the 2023 Form 10-K

Frequently Asked Questions

  1. What did Halozyme preliminarily estimate for 2023 revenue and royalties?

    The company estimated 2023 revenue in the range of $827 million to $832 million and 2023 royalties in the range of $445 million to $450 million.

  2. Why did the company adjust its Non-GAAP EPS so significantly?

    The Non-GAAP adjustments exclude items including amortization of intangible assets ($0.55 per share), share-based compensation ($0.27 per share), and amortization of debt discount ($0.05 per share), partly offset by a gain on changes in fair value of a contingent liability ($0.10 per share) and a prior year income tax benefit ($0.06 per share).

  3. What was the TLANDO Termination and how did it affect 2023 results?

    The TLANDO license agreement was terminated in September 2023. The filing states this produced a $13 million gain on changes in fair value of a contingent liability, a $4 million inventory write-off, and an impairment of TLANDO product rights intangible assets, which is included in amortization of intangible assets.

  4. How reliable are these preliminary estimates?

    The estimates are unaudited, subject to completion of financial and accounting close procedures, and based solely on information available to management as of the presentation date. The company states that results could vary materially from these estimates, and investors should not place undue reliance on them.

  5. Where can investors find the final audited 2023 results?

    The company states that final financial information will be filed with the SEC on its Form 10-K for the year ended December 31, 2023, once it becomes available.